denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), genomics, Plasma Cell Disorders, Diversity, Equity, and Inclusion (DEI) , Diseases, Lymphoid Malignancies, Biological Processes, Minimal Residual Disease , Clinical Practice (e.g. Guidelines, Health Outcomes and Services, and Survivorship, Value; etc.)
Description:
The treatment paradigm of multiple myeloma (MM) has dramatically changed over the past decade, offering many patients the chance for excellent disease control and longer survival. However, not every patient can tolerate the intensity of some interventions, while a subset of MM patients with high-risk disease likely should receive escalated therapy. In addition, the proper and complete assessment and categorization of patients is therefore mandatory. This educational session will explore emerging evidence in the assessment and management of newly diagnosed and relapsed MM patients and cover clinical, diagnostic, and radiographic evaluations.
Dr. Ciara Freeman will focus on the older, transplant ineligible myeloma patient population. Providers who treat myeloma will see an increasing volume of elderly patients for initial evaluation and subsequent lines of therapy. Older MM adults are more likely to be under- than over-treated, and therefore more objective (and ideally straightforward) ways to evaluate their fitness and ability to tolerate therapy will increasingly assist in decision making. The aim of this review is to highlight some of the approaches possible, how results might inform treatment selection, and illustrate ways that patients can be optimized for, rather than excluded from, the more complex therapies newly available.
Dr. Timothy Schmidt will discuss the challenges of defining and identifying high risk myeloma. A significant number of MM patients experience dramatically shorter disease-free intervals compared to “standard risk” patients. Dr. Schmidt will cover the development of both various biologic and molecular markers, as well as clinical data that can be used to define risk. In addition, he will review various treatment strategies that are explicitly employed for this group of patients.
Dr. Taxiarchis Kourelis will explore recent developments in minimal residual disease testing, imaging, new biomarkers and their roles in risk assessment. The incorporation of more modern techniques such as 18FDG-positive emission tomography and magnetic resonance imaging, in various iterations, have led to an appreciation of the spacial heterogeneity of myeloma tumor deposits encountered among myeloma patients and to the realization of the inadequacy of traditional bone surveys. Dr. Kourelis will also review recent data that underscore the predictive power of such techniques to stratify risk and help guide treatment decision. He will also consider the role of MRD testing and the use of mass spectrometry to predict risk of progression and relapse.
Dr. Ciara Freeman will focus on the older, transplant ineligible myeloma patient population. Providers who treat myeloma will see an increasing volume of elderly patients for initial evaluation and subsequent lines of therapy. Older MM adults are more likely to be under- than over-treated, and therefore more objective (and ideally straightforward) ways to evaluate their fitness and ability to tolerate therapy will increasingly assist in decision making. The aim of this review is to highlight some of the approaches possible, how results might inform treatment selection, and illustrate ways that patients can be optimized for, rather than excluded from, the more complex therapies newly available.
Dr. Timothy Schmidt will discuss the challenges of defining and identifying high risk myeloma. A significant number of MM patients experience dramatically shorter disease-free intervals compared to “standard risk” patients. Dr. Schmidt will cover the development of both various biologic and molecular markers, as well as clinical data that can be used to define risk. In addition, he will review various treatment strategies that are explicitly employed for this group of patients.
Dr. Taxiarchis Kourelis will explore recent developments in minimal residual disease testing, imaging, new biomarkers and their roles in risk assessment. The incorporation of more modern techniques such as 18FDG-positive emission tomography and magnetic resonance imaging, in various iterations, have led to an appreciation of the spacial heterogeneity of myeloma tumor deposits encountered among myeloma patients and to the realization of the inadequacy of traditional bone surveys. Dr. Kourelis will also review recent data that underscore the predictive power of such techniques to stratify risk and help guide treatment decision. He will also consider the role of MRD testing and the use of mass spectrometry to predict risk of progression and relapse.